Luke Evnin, a director of Werewolf Therapeutics, Inc. (NASDAQ: HOWL), has sold 30,616 shares of the company’s stock in a transaction that took place on January 14, 2023. The shares were sold at an average price of $0.57, resulting in a total transaction value of $17,451.12. Following this sale, Evnin retains ownership of 2,236,055 shares, which are currently valued at approximately $1,274,551.35. This transaction indicates a 1.35% decrease in his overall ownership of the company’s stock.
The sale was officially disclosed in a filing with the Securities and Exchange Commission (SEC), which is accessible for public review. In light of recent market activity, this transaction has drawn attention from investors and analysts alike.
Stock Performance and Institutional Investment
On January 13, 2023, shares of Werewolf Therapeutics opened at $0.55. The company’s stock performance metrics reveal a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Current trading data shows a fifty-day moving average of $0.84 and a two-hundred-day moving average of $1.23. Over the past year, the stock has experienced a 52-week low of $0.53 and a high of $2.38. Werewolf Therapeutics currently holds a market capitalization of $26.74 million and a price-to-earnings ratio of -0.34, with a beta of 0.77.
Recent activities by institutional investors have influenced the stock’s dynamics. For instance, Quadrature Capital Ltd initiated a new position valued at approximately $28,000 during the second quarter. Similarly, Qube Research & Technologies Ltd acquired shares worth about $48,000. Other notable investments include AQR Capital Management LLC at $79,000 and Y Intercept Hong Kong Ltd with an investment of around $92,000. Bridgeway Capital Management LLC increased its holdings by 157.7%, now owning 102,000 shares valued at $111,000. Collectively, institutional investors and hedge funds own approximately 64.84% of the company’s stock.
Analysts React to Recent Developments
Market analysts have provided various insights regarding Werewolf Therapeutics. On December 19, 2022, Citigroup downgraded the stock from a “market outperform” to a “market perform” rating. Meanwhile, Bank of America adjusted their target price from $8.00 to $7.00, maintaining a “buy” rating. In another notable shift, HC Wainwright reduced their price objective from $10.00 to $4.00 while keeping a “buy” rating.
Other firms also revised their ratings, with Weiss Ratings issuing a “sell (d-)” rating and Wedbush changing their stance from “outperform” to “neutral,” setting a target price of $1.00. The consensus rating among analysts now suggests a “Hold” for the stock, with an average target price of $3.75 based on data from MarketBeat.
About Werewolf Therapeutics
Founded as a clinical-stage biotechnology company, Werewolf Therapeutics is dedicated to advancing next-generation immunotherapies aimed at treating solid tumors. Their innovative Conditional Activation Platform is engineered to maintain therapeutic molecules in an inert state within healthy tissues, activating them selectively within the tumor microenvironment. This approach aims to enhance anti-tumor efficacy while reducing systemic toxicity. The company is currently advancing multiple programs, including conditionally activated cytokine candidates and bi-specific antibody constructs.
As market dynamics continue to evolve, stakeholders are encouraged to monitor developments closely.
